Jane Street Group LLC Grows Position in SI-BONE, Inc. (NASDAQ:SIBN)

Jane Street Group LLC raised its stake in SI-BONE, Inc. (NASDAQ:SIBN) by 29.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 77,359 shares of the company’s stock after purchasing an additional 17,410 shares during the period. Jane Street Group LLC owned 0.18% of SI-BONE worth $1,081,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Millrace Asset Group Inc. purchased a new stake in SI-BONE during the 3rd quarter worth approximately $1,056,000. Champlain Investment Partners LLC boosted its position in SI-BONE by 14.7% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock worth $39,145,000 after purchasing an additional 358,821 shares in the last quarter. Impax Asset Management Group plc increased its holdings in shares of SI-BONE by 41.3% during the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock valued at $10,604,000 after purchasing an additional 221,604 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of SI-BONE by 22.8% during the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock valued at $25,685,000 after purchasing an additional 368,637 shares in the last quarter. Finally, Divisadero Street Capital Management LP purchased a new stake in SI-BONE in the 2nd quarter worth $1,552,000. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SI-BONE Stock Down 0.1 %

Shares of SIBN opened at $13.71 on Tuesday. The stock has a market capitalization of $574.97 million, a PE ratio of -14.90 and a beta of 1.20. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $21.64. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The company’s 50-day simple moving average is $13.46 and its 200-day simple moving average is $14.09.

Insider Transactions at SI-BONE

In related news, insider Anthony J. Recupero sold 3,937 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $12.60, for a total transaction of $49,606.20. Following the sale, the insider now directly owns 228,554 shares in the company, valued at approximately $2,879,780.40. This represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Anshul Maheshwari sold 2,439 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.68, for a total transaction of $30,926.52. Following the sale, the chief financial officer now owns 194,623 shares in the company, valued at $2,467,819.64. The trade was a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,679 shares of company stock valued at $276,439. 3.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Truist Financial upped their target price on shares of SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 target price on shares of SI-BONE in a report on Wednesday, November 20th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE currently has a consensus rating of “Buy” and an average target price of $23.00.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.